U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

National Clinical Guideline Centre (UK). Urinary Incontinence in Neurological Disease: Management of Lower Urinary Tract Dysfunction in Neurological Disease. London: Royal College of Physicians (UK); 2012 Aug. (NICE Clinical Guidelines, No. 148.)

Cover of Urinary Incontinence in Neurological Disease

Urinary Incontinence in Neurological Disease: Management of Lower Urinary Tract Dysfunction in Neurological Disease.

Show details

Appendix LReferences – All Appendices

1.
Schurch B, De S, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. Journal of Urology. 2005;174(1):196–200. [PubMed: 15947626]
2.
Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized double-blind trial. Neurourology and Urodynamics. 2009;28(7):608–609. [PubMed: 21497851]
3.
Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. European Urology. 2011;60(4):742–750. [PubMed: 21798658]
4.
Office for National Statistics. Life tables. 2011. [Last accessed: 1 April 2011].
5.
Frankel HL, Coll JR, Charlifue SW, Whiteneck GG, Gardner BP, Jamous MA, et al. Long-term survival in spinal cord injury: a fifty year investigation. Spinal Cord. 1998;36(4):266–274. [PubMed: 9589527]
6.
National Institute for Health and Clinical Excellence. The Guidelines Manual. London: National Institute for Health and Clinical Excellence; 2009. Available from: http://www​.nice.org.uk​/aboutnice/howwework​/developingniceclinicalguidelines​/clinicalguidelinedevelopmentmethods​/GuidelinesManual2009.jsp. [PubMed: 27905714]
7.
Koehler E, Brown E, Haneuse SJ. On the assessment of Monte Carlo error in simulation-based statistical analyses. American Statistician. 2009;63(2):155–162. [PMC free article: PMC3337209] [PubMed: 22544972]
8.
Pannek J, Gocking K, Bersch U. Long-term effects of repeated intradetrusor botulinum neurotoxin a injections on detrusor function in patients with neurogenic bladder dysfunction. BJU International. 2009;104(9):1246–1250. [PubMed: 19426192]
9.
Apostolidis A, Jacques TS, Freeman A, Kalsi V, Popat R, Gonzales G, et al. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. European Urology. 2008;53(6):1245–1253. [PubMed: 18343564]
10.
Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology. 2006;68(6):1193–1197. [PubMed: 17141831]
11.
Reyblat P, Chan KG, Josephson DY, Stein JP, Freeman JA, Grossfeld GD, et al. Comparison of extraperitoneal and intraperitoneal augmentation enterocystoplasty for neurogenic bladder in spinal cord injury patients. World Journal of Urology. 2009;27(1):63–68. [PubMed: 19020878]
12.
Metcalfe PD, Cain MP, Kaefer M, Gilley DA, Meldrum KK, Misseri R, et al. What is the need for additional bladder surgery after bladder augmentation in childhood? Journal of Urology. 2006;176(4 Pt 2):1801–1805. [PubMed: 16945653]
13.
Game X, Castel-Lacanal E, Bentaleb Y, Thiry-Escudie I, de Boissezon X, Malavaud B, et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. European Urology. 2008;53(3):613–618. [PubMed: 17804150]
14.
Hollingworth W, Campbell JD, Kowalski J, Ravelo A, Girod I, Briggs A, et al. Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes. Quality of Life Research. 2010;19(3):323–331. [PubMed: 20094804]
15.
Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D Scores for the United Kingdom. Medical Decision Making. 2011;31(6):800–804. [PubMed: 21422468]
16.
Department of Health. NHS Reference Costs 2009–2010. London: Department of Health; 2011.
17.
Joint Formulary Committee. British National Formulary (BNF). 60 edition. London: British Medical Association and The Royal Pharmaceutical Society of Great Britain; 2010. Available from: http://www​.bnf.org.uk.
18.
Department of Health. NHSCat. UK: Department of Health; 2010. Available from: https://my​.supplychain.nhs.uk/catalogue.
19.
Curtis L. Personal Social Services Research Unit. Unit costs of health and social care. Canterbury: University of Kent; 2010.
20.
Padmanabhan P, Scarpero H, Milam D, Dmochowski R, Penson D. Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. World Journal of Urology. 2011;29(1):51–57. [PubMed: 21110030]
Copyright © 2012, National Clinical Guideline Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

Bookshelf ID: NBK132851

Views

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...